Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Entera Bio (NASDAQ:ENTX - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02, Zacks reports. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million.

Entera Bio Stock Down 4.1 %

Entera Bio stock traded down $0.07 during mid-day trading on Tuesday, hitting $1.63. 80,573 shares of the company's stock traded hands, compared to its average volume of 110,240. Entera Bio has a one year low of $1.41 and a one year high of $3.35. The firm has a 50 day moving average price of $2.11 and a 200 day moving average price of $2.02. The company has a market cap of $58.33 million, a PE ratio of -6.27 and a beta of 1.62.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Entera Bio in a research report on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.